Aktis Oncology (NASDAQ:AKTS) Stock Price Up 7.7% – Time to Buy?

Aktis Oncology (NASDAQ:AKTS) traded up 7.7% during mid-day trading on Monday . The stock traded as high as $25.07 and last traded at $25.92. 344,579 shares traded hands during mid-day trading, an increase of 3% from the average session volume of 334,544 shares. The stock had previously closed at $24.07.

Analyst Ratings Changes

AKTS has been the subject of several analyst reports. William Blair began coverage on Aktis Oncology in a report on Wednesday, April 29th. They set an “outperform” rating for the company. HC Wainwright boosted their price target on Aktis Oncology from $33.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, June 2nd. BMO Capital Markets initiated coverage on shares of Aktis Oncology in a report on Tuesday, August 18th. They set an “outperform” rating and a $37.00 price objective on the stock. Wall Street Zen lowered shares of Aktis Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, July 25th. Finally, Raymond James Financial started coverage on shares of Aktis Oncology in a research report on Monday, June 15th. They set a “strong-buy” rating and a $40.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Aktis Oncology currently has an average rating of “Moderate Buy” and an average price target of $35.00.

Aktis Oncology Price Performance

The firm has a market capitalization of $1.39 billion and a price-to-earnings ratio of -31.80. The business has a fifty day moving average price of $25.49 and a two-hundred day moving average price of $21.29.

Aktis Oncology (NASDAQ:AKTS) last released its earnings results on Thursday, August 13th. The technology company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.01). The company had revenue of $3.38 million during the quarter, compared to analysts’ expectations of $2.70 million. On average, research analysts predict that Aktis Oncology will post -1.8 earnings per share for the current year.

Insider Transactions at Aktis Oncology

In other Aktis Oncology news, Director Ken Herrmann sold 4,856 shares of the stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $24.56, for a total transaction of $119,263.36. Following the completion of the transaction, the director owned 3,506 shares of the company’s stock, valued at $86,107.36. This represents a 58.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. California State Teachers Retirement System acquired a new stake in Aktis Oncology during the 2nd quarter worth $288,000. Readystate Asset Management LP acquired a new stake in shares of Aktis Oncology in the second quarter valued at about $967,000. AXQ Capital LP purchased a new position in shares of Aktis Oncology in the second quarter worth about $226,000. Susquehanna International Group LLP acquired a new position in Aktis Oncology during the second quarter worth about $278,000. Finally, Alyeska Investment Group L.P. acquired a new position in Aktis Oncology during the second quarter worth about $9,347,000. 28.84% of the stock is owned by institutional investors and hedge funds.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.